ライフサイエンスコーパス: routine immunization

1 %) for including safe injection equipment in routine immunization.

2 irus are safe, effective and recommended for routine immunization.

3 need for additional activities to complement routine immunization.

4 be targeted by future campaigns and catch-up routine immunization.

5 vated poliovirus vaccine and bivalent OPV in routine immunization.

6 sed respiratory support and intubation after routine immunization.

7 gns and 3 trivalent OPV (tOPV) doses through routine immunization.

8 tries after administration of SP-IPTi during routine immunizations.

9 oduced fewer local reactions than concurrent routine immunizations.

10 schedules, causing the omission or delay of routine immunizations.

11 d a control district where workers conducted routine immunization activities without health behavior

12 tration and defaulter tracing, monitoring of routine immunization activities, and support of district

13 aining high vaccination coverage through the routine immunization activity infrastructure, thus creat

14 a novel typhoid conjugate vaccine (TCV) into routine immunization along with catch-up campaigns for c

15 ) improving outbreak response, (5) enhancing routine immunization and activities implemented between

16 dministering oral poliovirus vaccine through routine immunization and annual national immunization da

17 Rotary is providing additional support for routine immunization and healthcare.

18 We estimated routine immunization and influenza vaccination campaign

19 but later expanded its messaging to promote routine immunization and other health and sanitation int

20 ovirus vaccine or exposure to OPV virus from routine immunization and recent injections could explain

21 sider introducing a fIPV strategy into their routine immunization and supplementary immunization acti

22 s to questions about health behaviors during routine immunizations and providing targeted counseling.

23 of national immunization days, strengthening routine immunization, and carrying-out mopping-up activi

24 acute flaccid paralysis (AFP) surveillance, routine immunization, and polio supplemental immunizatio

25 The objective includes strengthening routine immunization as the primary pillar to sustaining

26 s on coronavirus disease 2019 (COVID-19) and routine immunization as well as trust in pandemic inform

27 Routine immunization at 9 months of age resulted in lowe

28 r); (2) preventive vaccination campaign; (3) routine immunization at 9 months; and (4) a combination

29 ful policy dialogue about polio vaccines and routine immunization at multiple levels.

30 f experience integrating other services with routine immunization at outreach sessions.

31 l vaccine (group 3; n=62), administered with routine immunizations at 2, 3, and 4 months of age.

32 e settings, vaccination campaigns supplement routine immunization but often fail to achieve coverage

33 lation received smallpox vaccinations before routine immunization ceased in 1972 for civilians and in

34 Infants received routine immunization: combination diphtheria vaccine (di

35 Routine immunization could be strengthened in areas wher

36 surveillance starting in 2004; and conducted routine immunization coverage and seroprevalence surveys

37 h-risk pockets witnessed an increase in full routine immunization coverage.

38 ter OPV cessation in areas with insufficient routine immunization coverage.

39 viewed country reports on MACV campaigns and routine immunization data reported to the World Health O

40 ecommendations for improved surveillance and routine immunization during the health system decentrali

41 The practice of routine immunization has reshaped our view of pediatric

42 the growing neglect of societal adherence to routine immunizations has prompted the Medical Advisory

43 The limitations of this study are unknown routine immunization history and poor retention of vacci

44 icly available sources, to project costs for routine immunization, immunization campaigns, surveillan

45 ctivities in 236 districts, and strengthened routine immunization in 100 districts.

46 After its global withdrawal from routine immunization in 2016, outbreak response use has

47 ation and city location were associated with routine immunization in August 2000 (71% vs 25% [P =.003

48 tivated poliovirus vaccine, strengthening of routine immunization in countries with extensive polio r

49 of this conjugate vaccine concurrently with routine immunization in infants is planned.

50 iew Committee (ERC) on Polio Eradication and Routine Immunization in Nigeria recommended that social

51 ch efforts should also be adopted to support routine immunization, introduction of new vaccines, and

52 Pakistan, and children remain at risk unless routine immunization is strengthened or additional suppl

53 building in countries where surveillance and routine immunization lag behind other health priorities.

54 Cases were undervaccinated through routine immunization (matched odds ratio [MOR], 0.3; 95%

55 Beginning in 2005, the US implemented routine immunization of adolescents with a quadrivalent

56 s vaccines are available and recommended for routine immunization of all infants.

57 Routine immunization of children has the potential to re

58 Routine immunization of children with the heptavalent pn

59 rus vaccine (RV1) with intussusception after routine immunization of infants in Mexico and Brazil.

60 cine is recommended in the United States for routine immunization of infants.

61 type b conjugate vaccines were licensed for routine immunization of infants.

62 tal sepsis and project the global effects of routine immunization of pregnant women with the K. pneum

63 PV in countries currently using OPV only for routine immunization offers protection from paralysis to

64 cellular pertussis vaccine either as part of routine immunization or for outbreak control should be e

65 sitant to vaccinate their children may delay routine immunizations or seek exemptions from state vacc

66 rveillance, vaccination campaigns, increased routine immunization outreach sessions, and strengthenin

67 data management, alternatives for measuring routine immunization performance should be considered.

68 ution model to explore the impact of various routine immunization policies involving IPV on populatio

69 Hygiene kit distribution during routine immunizations positively impacted household wate

70 ad range of circulating strains as part of a routine immunization program >5 years after its introduc

71 eria because of low coverage achieved in the routine immunization program and in supplementary immuni

72 by NITAGs in the introduction of IPV in the routine immunization program and the lessons learned.

73 al African Republic introduced MACV into its routine immunization program immediately after the mass

74 cine (IPV) at >/=14 weeks of age through the routine immunization program in countries currently not

75 The routine immunization program information collected inclu

76 16, 11 EMR countries introduced IPV in their routine immunization program, including all of the count

77 ab, Bangladesh, HRV was included in Matlab's routine immunization program.

78 -dose vaccines requires a robust stand-alone routine immunization program.

79 rform critical tasks in the strengthening of routine immunization programs and the control of measles

80 tive campaigns followed by introduction into routine immunization programs in 8 of these countries.

81 Strengthened routine immunization programs in countries with suboptim

82 the stage for the introduction of TCVs into routine immunization programs in endemic countries.

83 of inactivated polio vaccine (IPV) into the routine immunization programs of all countries using ora

84 entifying gaps in the polio surveillance and routine immunization programs, and provided recommendati

85 ies have introduced MACV into their national routine immunization programs, including 7 with catch-up

86 ng with the type 2 component; and strengthen routine immunization programs-set an ambitious series of

87 ns and to begin vaccine safety monitoring in routine immunization programs.

88 as country plans for MACV introduction into routine immunization programs.

89 levels of intensity of polio vaccine use in routine immunization programs.

90 ta management and quality, and strengthening routine immunization programs.

91 ation and the implications for triggered and routine immunization programs.

92 zone impedes the establishment of effective routine immunization programs.

93 ontrol strategy coupled with the delivery of routine immunizations recommended by the World Health Or

94 frica and the WHO Executive Board to ramp up routine immunization (RI) activities, began to intensify

95 nts at high risk for polio transmission with routine immunization (RI) and other selected primary hea

96 he impact of polio eradication activities on routine immunization (RI) and primary healthcare (PHC).

97 m was undertaken, with specific focus on the routine immunization (RI) component.

98 ing, and a renewed emphasis on strengthening routine immunization (RI) programs.

99 ced inactivated polio vaccine (IPV) into its routine immunization (RI) schedule in March 2015 and was

100 The potential to strengthen routine immunization (RI) services through supplementary

101 (DTP3), which is typically delivered through routine immunization (RI), with those of measles-contain

102 Recent changes in the routine immunization schedule and a renewed emphasis on

103 Adding a single IPV dose to an OPV-only routine immunization schedule at or just before OPV cess

104 d dose of varicella vaccine was added to the routine immunization schedule for children in June 2006

105 io vaccine 2 was globally withdrawn from the routine immunization schedule in 2016, soon after the ce

106 accine (IPV) after its introduction into the routine immunization schedule in Bangladesh.

107 us (HPV) vaccination was introduced into the routine immunization schedule in the United States in la

108 introduction of the varicella vaccine to the routine immunization schedule, we have observed a 70% re

109 2002, as PCV7 was being introduced into the routine immunization schedule.

110 e vaccines are an expensive component of the routine immunization schedule.

111 ntradermal fractional-dose IPV (fIPV) in its routine immunization schedule.

112 ng injectable vaccines delivered through the routine immunization schedule: diphtheria-tetanus-pertus

113 ental to relevant stakeholders when planning routine immunization schedules and supplemental immuniza

114 dose of Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2015.

115 f inactivated polio vaccine (IPV) into their routine immunization schedules by the end of 2015.

116 ntroduction of at least one dose of IPV into routine immunization schedules in 126 all OPV-using coun

117 dose of inactivated poliovirus vaccine into routine immunization schedules, and it describes the pro

118 Opportunities to strengthen the routine immunization service and health system should be

119 nsider funding to maintain and to strengthen routine immunization services and other maternal, neonat

120 eradication goal is its potential impact on routine immunization services and the overall health sys

121 This legacy also includes support for routine immunization services and vaccine introductions

122 Rapid scale-up and strengthening of routine immunization services to reach children and to d

123 rastructure than MSs, including provision of routine immunization services.

124 zation campaigns, and the urgency to improve routine immunization services.

125 s in vaccination campaigns and strengthening routine immunization services.

126 icators associated with AFP surveillance and routine immunization, showing statistically significant

127 prompt detection of outbreaks, but its weak routine immunization system means that supplementary imm

128 Efforts are underway to strengthen Nigeria's routine immunization system, yet measuring impact poses

129 n immunity than can be achieved in a growing routine immunization system.

130 lenges include a decline in funding and weak routine immunization systems in some countries.

131 Limited resources for surveillance and routine immunization systems in the region indicate a ri

132 have received to conduct tasks to strengthen routine immunization systems, and the type of tasks they

133 f Sabin 2 oral poliovirus vaccine (OPV) from routine immunization, the Global Polio Eradication Initi

134 VIs can provide an opportunity to strengthen routine immunization, through strengthening program mana

135 need of optimal vaccination coverage during routine immunization to build up and sustain the immunit

136 introduction of inactivated polio vaccine in routine immunization to mitigate against risk of vaccine

137 Routine immunization using the meningococcal conjugate v

138 airs were enrolled at presentation for their routine immunization visit in Soweto, South Africa, when

139 n 10,095 children 1 to 2 years of age during routine immunization visits.

140 Failure to vaccinate through routine immunization was a major risk factor for poliomy

141 Planning started early, routine immunization was strengthened, and technical and

142 isseminated vaccine strain measles following routine immunization, whereas an infant brother died aft

143 Routine immunization with 2 full or fractional doses of

144 es a need to improve global coverage through routine immunization with inactivated polio vaccine (IPV

145 To investigate the extent to which routine immunization with intramuscularly injected inact

146 ndings provide policy-relevant evidence that routine immunization with IPV may induce nasal and phary

147 In future, how might intensive, routine immunization with novel vaccines compare against

148 Between 2015 and 2035, routine immunization with or without a catch-up campaign

149 Routine immunization with pneumococcal conjugate vaccine

150 s, acute flaccid paralysis surveillance, and routine immunization with the support of the surge capac